Abstract
Recent clinical trials have refined our understanding of how the glycoprotein (GP) IIb/IIIa inhibitors should best be used. These trials examined whether there are clinical differences between agents, whether empiric use of GP IIb/IIIa inhibitors in acute coronary syndromes is justified, and whether these drugs might allow for early invasive management in acute coronary syndromes.
| Original language | English |
|---|---|
| Pages (from-to) | 1017-1023 |
| Number of pages | 7 |
| Journal | Cleveland Clinic Journal of Medicine |
| Volume | 68 |
| Issue number | 12 |
| DOIs | |
| State | Published - 2001 |
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'GP IIb/IIIa inhibitors in coronary artery disease management: What the latest trials tell us'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver